查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1608077

In Silico藥物發現市場：按分子類型、工作流程、治療領域和最終用戶 - 2025-2030 年全球預測

In-Silico Drug Discovery Market by Molecule Type (Antibodies, Nucleic Acids, Peptides), Workflow (Bioinformatics, Clinical Trials, Discovery), Therapeutic Area, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023 年，In Silico藥物發現市值為 26.9 億美元，預計到 2024 年將達到 28.6 億美元，複合年成長率為 8.71%，到 2030 年將達到 48.3 億美元。

In Silico藥物發現利用計算方法來設計和最佳化藥物，透過加快藥物開發步伐並降低相關成本，正在重新定義製藥業。它包括電腦輔助藥物設計、分子建模和預測藥物與其標靶之間相互作用的模擬。對In Silico方法的需求源自於提高研發生產力的迫切需求。這些技術將應用於先導化合物的識別、最佳化和毒性預測，以提高藥物開發的準確性。最終用戶主要是製藥公司、生技公司、研究機構和學術機構。該市場是由處方分析的顯著進步、處理器功能的增強以及對個人化藥物的需求不斷成長所推動的。此外，人工智慧和機器學習的日益採用將進一步提高藥物發現過程的效率。一個關鍵的機會在於快速發展的基因組學領域，其中促進根據基因圖譜客製化的個人化藥物發現In Silico工具正在吸引大量的研究和投資。然而，這個市場面臨著初始成本高、資料隱私問題以及缺乏熟悉計算技術的熟練人員等挑戰。準確複製複雜生物系統的技術限制也仍然是一個障礙。專注於結合電腦模擬、體外和體內資料的整合平台的創新可以提供競爭優勢。雲端基礎的靈活建模和協作解決方案也具有改變產業的巨大潛力。公司應優先開發直覺的使用者介面和培訓計劃，以克服技能差距。總體而言，由於技術進步和綜合療法相關的機遇，In Silico藥物發現市場呈現出充滿希望的前景，而克服經濟和技術挑戰將是成長的條件。

主要市場統計
基準年[2023] 26.9億美元
預測年份 [2024] 28.6億美元
預測年份 [2030] 48.3億美元
複合年成長率（%） 8.71%

市場動態：揭示快速發展的電腦In Silico藥物發現市場的關鍵市場洞察

供需的動態交互作用正在改變In Silico藥物發現市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 疾病盛行率上升和藥物發現
    • 改進計算模型和模擬
    • 個性化醫療的趨勢
  • 市場限制因素
    • 資料整合問題
  • 市場機會
    • 先進技術在In Silico藥物發現的整合
    • 持續研究和開發，推動In Silico藥物發現創新
  • 市場挑戰
    • 流程複雜且缺乏熟練的專業人員

波特五力：駕馭In Silico藥物發現市場的策略工具

波特的五力框架是了解In Silico藥物發現市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解電腦In Silico藥物發現市場的外部影響

外部宏觀環境因素在塑造In Silico藥物發現市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解In Silico藥物發現市場的競爭狀況

In Silico藥物發現市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

In Silico藥物發現市場 FPNV 定位矩陣中供應商的績效評估

FPNV 定位矩陣是評估In Silico藥物發現市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製電腦模擬In Silico發現市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，In Silico藥物發現市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 疾病傳播和新藥發現的增加
      • 改進計算模型和模擬
      • 個性化醫療方法的趨勢
    • 抑制因素
      • 資料整合問題
    • 機會
      • 將先進技術融入In Silico藥物發現中
      • 持續研究和開發，推動In Silico藥物發現創新
    • 任務
      • 流程複雜且缺乏熟練的專業人員
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第 6 章按分子類型In Silico藥物發現市場

  • 抗體
  • 核酸
  • 胜肽
  • 蛋白質
  • 向量

第 7 章In Silico藥物發現市場：依工作流程

  • 生物資訊學
  • 臨床試驗
  • 發現
  • 臨床前測試
  • 蛋白質結構預測
  • 反向對接
  • 目標識別

第 8 章按治療領域In Silico藥物發現市場

  • 血液疾病
  • 感染疾病
  • 精神障礙
  • 代謝紊亂
  • 肌肉骨骼疾病
  • 神經系統疾病
  • 腫瘤性疾病
  • 呼吸系統疾病
  • 皮膚病

第 9 章In Silico藥物發現市場：按最終用戶

  • 學術研究所
  • 合約調查機構
  • 藥品製造商

第 10 章 美洲In Silico藥物發現市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區In Silico藥物發現市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的In Silico藥物發現市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abzena Ltd.
  • Aragen Life Sciences Pvt. Ltd.
  • BioDuro LLC
  • BioNTech SE
  • Certara, Inc.
  • Charles River Laboratories International, Inc.
  • Chemical Computing Group ULC
  • ChemPartner PharmaTech Co Ltd
  • Creative Biostructure
  • Curia Global Inc.
  • Evotec SE
  • GenScript Biotech Corporation
  • InSilico Medicine
  • Ligand Pharmaceuticals Incorporated
  • Schrodinger Inc.
  • Selvita SA
  • Simulations Plus, Inc.
  • Sygnature Discovery
  • Viva Biotech Holding Group
  • WuXi AppTec
Product Code: MRR-2E76C3E47FCA

The In-Silico Drug Discovery Market was valued at USD 2.69 billion in 2023, expected to reach USD 2.86 billion in 2024, and is projected to grow at a CAGR of 8.71%, to USD 4.83 billion by 2030.

In-silico drug discovery, which leverages computational methods to design and optimize drugs, is redefining the pharmaceutical landscape by accelerating the pace of drug development and reducing associated costs. It encompasses computer-aided drug design, molecular modeling, and simulations to predict interactions between drugs and their targets. The necessity of in-silico approaches stems from the pressing need to enhance R&D productivity, especially as traditional methods prove costly and time-consuming. These technologies find application in lead identification, optimization, and toxicity prediction, enhancing the precision of drug development. End-users primarily include pharmaceutical and biotechnology companies, research organizations, and academic institutions. The market is poised for growth, driven by significant prescriptive analytics advancements, enhanced processor capabilities, and escalating demand for personalized medicines. Additionally, the increasing adoption of AI and machine learning further boosts efficiency in drug discovery processes. A key opportunity lies in the burgeoning field of genomics, with in-silico tools facilitating personalized drug discovery tailored to genetic profiles, thereby attracting substantial research and investment. However, this market faces challenges such as high initial costs, data privacy concerns, and a shortage of skilled personnel proficient in computational methods. Technological limitations in accurately replicating the complexity of biological systems remain a hurdle. Innovations focusing on integrated platforms combining in-silico, in-vitro, and in-vivo data could provide competitive advantages. Cloud-based solutions for flexible modeling and collaboration also hold significant potential for transformative industry change. Companies should prioritize developing intuitive user interfaces and training programs to overcome the skills gap. Overall, while the in-silico drug discovery market presents a promising horizon with opportunities tied to technological advancement and integrated therapies, growth is contingent upon navigating economic and technical challenges.

KEY MARKET STATISTICS
Base Year [2023] USD 2.69 billion
Estimated Year [2024] USD 2.86 billion
Forecast Year [2030] USD 4.83 billion
CAGR (%) 8.71%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving In-Silico Drug Discovery Market

The In-Silico Drug Discovery Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of diseases and increase in drug discovery
    • Improvement in computational models and simulations
    • Inclination towards personalized medicine approach
  • Market Restraints
    • Concerns associated with data integration
  • Market Opportunities
    • Integration of advanced technologies in in-silico drug discovery
    • Ongoing R&D to drive innovation in in-silico drug discovery
  • Market Challenges
    • Complex process and dearth of skilled professionals

Porter's Five Forces: A Strategic Tool for Navigating the In-Silico Drug Discovery Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the In-Silico Drug Discovery Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the In-Silico Drug Discovery Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the In-Silico Drug Discovery Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the In-Silico Drug Discovery Market

A detailed market share analysis in the In-Silico Drug Discovery Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the In-Silico Drug Discovery Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the In-Silico Drug Discovery Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the In-Silico Drug Discovery Market

A strategic analysis of the In-Silico Drug Discovery Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the In-Silico Drug Discovery Market, highlighting leading vendors and their innovative profiles. These include Abzena Ltd., Aragen Life Sciences Pvt. Ltd., BioDuro LLC, BioNTech SE, Certara, Inc., Charles River Laboratories International, Inc., Chemical Computing Group ULC, ChemPartner PharmaTech Co Ltd, Creative Biostructure, Curia Global Inc., Evotec SE, GenScript Biotech Corporation, InSilico Medicine, Ligand Pharmaceuticals Incorporated, Schrodinger Inc., Selvita S.A., Simulations Plus, Inc., Sygnature Discovery, Viva Biotech Holding Group, and WuXi AppTec.

Market Segmentation & Coverage

This research report categorizes the In-Silico Drug Discovery Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Molecule Type, market is studied across Antibodies, Nucleic Acids, Peptides, Proteins, and Vectors.
  • Based on Workflow, market is studied across Bioinformatics, Clinical Trials, Discovery, Preclinical Tests, Protein Structure Prediction, Reverse Docking, and Target Identification.
  • Based on Therapeutic Area, market is studied across Blood Disorders, Infectious Diseases, Mental Disorders, Metabolic Disorders, Musculoskeletal Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders, and Skin Disorders.
  • Based on End User, market is studied across Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical Manufacturers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of diseases and increase in drug discovery
      • 5.1.1.2. Improvement in computational models and simulations
      • 5.1.1.3. Inclination towards personalized medicine approach
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with data integration
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of advanced technologies in in-silico drug discovery
      • 5.1.3.2. Ongoing R&D to drive innovation in in-silico drug discovery
    • 5.1.4. Challenges
      • 5.1.4.1. Complex process and dearth of skilled professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. In-Silico Drug Discovery Market, by Molecule Type

  • 6.1. Introduction
  • 6.2. Antibodies
  • 6.3. Nucleic Acids
  • 6.4. Peptides
  • 6.5. Proteins
  • 6.6. Vectors

7. In-Silico Drug Discovery Market, by Workflow

  • 7.1. Introduction
  • 7.2. Bioinformatics
  • 7.3. Clinical Trials
  • 7.4. Discovery
  • 7.5. Preclinical Tests
  • 7.6. Protein Structure Prediction
  • 7.7. Reverse Docking
  • 7.8. Target Identification

8. In-Silico Drug Discovery Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Blood Disorders
  • 8.3. Infectious Diseases
  • 8.4. Mental Disorders
  • 8.5. Metabolic Disorders
  • 8.6. Musculoskeletal Disorders
  • 8.7. Neurological Disorders
  • 8.8. Oncological Disorders
  • 8.9. Respiratory Disorders
  • 8.10. Skin Disorders

9. In-Silico Drug Discovery Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Contract Research Organizations
  • 9.4. Pharmaceutical Manufacturers

10. Americas In-Silico Drug Discovery Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific In-Silico Drug Discovery Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa In-Silico Drug Discovery Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abzena Ltd.
  • 2. Aragen Life Sciences Pvt. Ltd.
  • 3. BioDuro LLC
  • 4. BioNTech SE
  • 5. Certara, Inc.
  • 6. Charles River Laboratories International, Inc.
  • 7. Chemical Computing Group ULC
  • 8. ChemPartner PharmaTech Co Ltd
  • 9. Creative Biostructure
  • 10. Curia Global Inc.
  • 11. Evotec SE
  • 12. GenScript Biotech Corporation
  • 13. InSilico Medicine
  • 14. Ligand Pharmaceuticals Incorporated
  • 15. Schrodinger Inc.
  • 16. Selvita S.A.
  • 17. Simulations Plus, Inc.
  • 18. Sygnature Discovery
  • 19. Viva Biotech Holding Group
  • 20. WuXi AppTec

LIST OF FIGURES

  • FIGURE 1. IN-SILICO DRUG DISCOVERY MARKET RESEARCH PROCESS
  • FIGURE 2. IN-SILICO DRUG DISCOVERY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. IN-SILICO DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. IN-SILICO DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IN-SILICO DRUG DISCOVERY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IN-SILICO DRUG DISCOVERY MARKET DYNAMICS
  • TABLE 7. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY NUCLEIC ACIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PRECLINICAL TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY REVERSE DOCKING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MENTAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SKIN DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. PHILIPPINES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. SINGAPORE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SINGAPORE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 96. SINGAPORE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. SOUTH KOREA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. SOUTH KOREA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 100. SOUTH KOREA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 101. SOUTH KOREA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. TAIWAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. TAIWAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 104. TAIWAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 105. TAIWAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. THAILAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. THAILAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 108. THAILAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 109. THAILAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. VIETNAM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. VIETNAM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 112. VIETNAM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 113. VIETNAM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 119. DENMARK IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. DENMARK IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 121. DENMARK IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 122. DENMARK IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. EGYPT IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. EGYPT IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 125. EGYPT IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 126. EGYPT IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. FINLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. FINLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 129. FINLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 130. FINLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. FRANCE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. FRANCE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 133. FRANCE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 134. FRANCE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. GERMANY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. GERMANY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 137. GERMANY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 138. GERMANY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. ISRAEL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. ISRAEL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 141. ISRAEL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 142. ISRAEL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. ITALY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. ITALY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 145. ITALY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 146. ITALY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. NETHERLANDS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NETHERLANDS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 149. NETHERLANDS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 150. NETHERLANDS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. NIGERIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. NIGERIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 153. NIGERIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 154. NIGERIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. NORWAY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. NORWAY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 157. NORWAY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 158. NORWAY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. POLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. POLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 161. POLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 162. POLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. QATAR IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. QATAR IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 165. QATAR IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 166. QATAR IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. RUSSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. RUSSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 169. RUSSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 170. RUSSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. SAUDI ARABIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SAUDI ARABIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 173. SAUDI ARABIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 174. SAUDI ARABIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. SPAIN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SPAIN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 181. SPAIN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 182. SPAIN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. SWEDEN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. SWEDEN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 185. SWEDEN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 186. SWEDEN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. SWITZERLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. SWITZERLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 189. SWITZERLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 190. SWITZERLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. TURKEY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. TURKEY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 193. TURKEY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 194. TURKEY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED ARAB EMIRATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED ARAB EMIRATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED ARAB EMIRATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 198. UNITED ARAB EMIRATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 199. UNITED KINGDOM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. UNITED KINGDOM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 201. UNITED KINGDOM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 202. UNITED KINGDOM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. IN-SILICO DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 204. IN-SILICO DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2023